Public-registry trials using Seviteronel: given orally once daily in 28 day cycles that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | Innocrin Pharmaceutical | Castration-resistant Prostate Cancer | PHASE2 | 23 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →